Lenalidomide for Multiple Myeloma
This study is evaluating whether maintenance therapy can help people who have been treated for myeloma.
See full descriptionAbout the trial for Multiple Myeloma
Treatment Groups
This trial involves 2 different treatments. Lenalidomide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for Phase 1 and Phase II: Event Free Survival and Overall Survival
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Lenalidomide will improve 1 primary outcome in patients with Multiple Myeloma. Measurement will happen over the course of 5 years.
Patient Q & A Section
Does multiple myeloma run in families?
This family highlights the familial nature of myeloma. All three familial cases investigated herein had at least one affected sibling with MM. The detection of mutations in BRCA1 and BRCA2 in two of these cases suggests that BRCA may play a role in certain cases of myeloma. However, we were unable to identify the causal gene in any of the three cases.
Can multiple myeloma be cured?
The data do not support the general claim that [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) can be cured, nor the claim of specific cures for any specific subtype of myeloma.
What causes multiple myeloma?
Most of the cases of multiple myeloma were found in patients with prior light to moderate drinking of alcoholic beverages, while cigarette smoking was the most important factor associated with multiple myeloma.
What are common treatments for multiple myeloma?
Common treatment options for MM include standard therapies and clinical trials. In all, the 5-year survival rate for untreated MM is approximately 30%, meaning that some patients with MM seek out therapies specifically designed for their disease and the type of therapy they choose. While some patients choose to pursue different forms of treatment, including chemotherapy, steroids, or new biological strategies, others prefer standard approaches. Future research in this area should focus on more effective approaches to the treatment of MM, which would improve the survival rate, allowing patients to live longer and be more likely to pursue therapeutic approaches that would maximize their response to treatment and minimize their number of adverse effects. This article is protected by copyright. All rights reserved.
What are the signs of multiple myeloma?
The diagnosis of multiple myeloma is based on clinical and laboratory findings. The presence of anemia, increased serum IgM production, osteolytic lesions, renal osteodystrophy and bone pain are indicative of a multiple myeloma diagnosis. The presence of a solitary plasmacytoma of bone is a diagnostic challenge.
How many people get multiple myeloma a year in the United States?
About 19.8 million Medicare beneficiaries have been diagnosed with [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) in 1998. This makes up 3.5% of all Medicare beneficiaries and one sixth of multiple myeloma in the U. S. In 2000, 1.6 million patients were living with myeloma. In 2003, Medicare beneficiaries with multiple myeloma were estimated to use nearly $1 billion of medical services. Data from a recent study are consistent with the results of earlier studies showing high annual incidence rates of multiple myeloma in the U. S. compared with most of the developed world.
What is multiple myeloma?
Multiple myeloma is a cancer that forms mainly in the bone marrow. The bone marrow is the site of formation for all plasma cells which leads to the formation of all symptomatic plasma cell neoplasms including multiple myeloma. It is the deadliest hematologic cancer and is estimated to affect more than 20,000 people in the United States. Multiple myeloma is considered to be underdiagnosed due to its heterogeneity and late stage of development. It is a disease with high morbidity and mortality and an increasing incidence rate. Multiple myeloma causes one of the highest fatality rates of any cancer in the United States.
Who should consider clinical trials for multiple myeloma?
Patients, their family members, physicians and patients are important partners to consider when designing and conducting clinical trial research. Patients are frequently not informed about potential risks, and they may not be willing to commit to an experimental treatment that could not affect their health status in any way. Physicians’ perspectives are often constrained by the burden of time, costs, and institutional priorities, and by a lack of scientific evidence for an intervention. Research shows the value of shared decision-making between patients and their healthcare providers to prevent potential trial non-adherence and to improve participants’ overall satisfaction with treatment. Clinicians also need educational materials addressing patients’ specific needs (e.g.
How quickly does multiple myeloma spread?
The early stages of primary MM progression are often undiagnosed, and thus there may be some cases of early staging of MM and improved outcomes from therapy. However, early MM progression is also typically a gradual process and patients often have advanced disease requiring intensive therapy.
Have there been other clinical trials involving lenalidomide?
We summarize the clinical trials completed on patients with MM using lenalidomide. These studies indicate that lenalidomide has shown some efficacy as previously reported. However, the optimal duration of lenalidomide treatment has yet to be defined.
What is the primary cause of multiple myeloma?
The primary cause of [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) is a (relatively) genetic abnormality of the cells of the [bone marrow], called monoclonal gammopathy. In the first few years of multiple myeloma, the [leukemia cells of the myeloma proliferate without being killed or stopped, thus the [clonal plasma cells of multiple myeloma are produced inside blood and bone marrow]; they stay in the bone marrow, and in bone marrow [smear] smears, [leukocytes are visible].